EFFECTS OF A BISPHOSPHONATE ON EXPERIMENTAL PERIODONTITIS IN MONKEYS
EFFECTS OF A BISPHOSPHONATE ON EXPERIMENTAL PERIODONTITIS IN MONKEYS
复制标题
DOI：
10.1902/jop.1992.63.10.825
复制
发表时间：
1992-10-01
影响因子：
4.3
通讯作者：
WOOD, R
中科院分区：
文献类型：
--
作者：
BRUNSVOLD, MA;CHAVES, ES;WOOD, R
双磷酸盐类已被证明可通过抑制破骨细胞活性增加雌激素缺乏患者的骨量。本研究的目的是测量双膦酸盐对猴子牙周炎发展的临床和放射学影响。研究了27只成年食蟹猴。隔离检疫后，获得基线数据，包括菌斑指数，牙龈指数，临床探测深度测量，和口内X光片。使用计算机辅助密度测定（CADIA）系统分析标准化X线片的骨密度定量变化。将动物分为3组，接受3种治疗药物中的1种;这些药物包括两种水平的试验药物（阿仑膦酸盐）和生理盐水安慰剂。每2周在小腿隐静脉注射一次药物，持续16周。开始治疗剂注射后一周，用3-0丝线结扎下颌右磨牙和前磨牙以诱导牙周炎。结扎的牙齿也接种牙龈卟啉单胞菌，以确保显着的病原学挑战。未结扎的同源牙作为对照。在结扎后8周和16周重复临床测量和X线片。浓度为0.05 mg/kg的双膦酸盐显著延缓牙周炎的进展，如通过骨密度变化所测量的。在骨密度损失方面，较高剂量的试验药物与安慰剂无差异。试验药物对临床指标无显著影响。改变骨代谢的药物可能为牙周病的治疗提供新的途径。
BISPHOSPHONATES HAVE BEEN SHOWN to increase bone mass in estrogen-deficient patients by inhibiting osteoclast activity. The purpose of this study was to measure clinical and radiographic effects of a bisphosphonate on periodontitis development in monkeys. Twenty-seven (27) adult cynomolgus monkeys were studied. After quarantine, baseline data were obtained including plaque index, gingival index, clinical probing depth measurements, and intraoral radiographs. Standardized radiographs were analyzed for quantitative changes in bone density using a computer assisted densitometric (CADIA) system. Animals were divided into 3 groups to receive 1 of the 3 treatment agents; these agents consisted of two levels of the test drug (alendronate) and a saline placebo. Agents were injected in the saphenous vein of the lower leg every 2 weeks for 16 weeks. One week after the initiation of treatment agent injections, mandibular right molars and premolars were ligated with 3-0 silk sutures to induce periodontitis. Ligated teeth were also inoculated with Porphyromonas gingivalis to insure a significant etiologic challenge. Non-ligated homologous teeth served as controls. Clinical measurements and radiographs were repeated at 8 and 16 weeks after ligation. The bisphosphonate at a concentration of 0.05 mg/kg significantly retarded the progression of periodontitis as measured by bone density changes. The higher level dose of the test drug did not differ from placebo with respect to loss of bone density. Clinical indices were not affected significantly by the test drugs. Drugs that alter bone metabolism may offer a new approach to the treatment of periodontal disease.